Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 201 results for dementia

  1. Social care trainers' resource

    (guideline CG170). Dementia Supporting people with dementia and their carers in health and social care (guideline CG42)...

  2. Anticholinergic burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual care?

    burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual...

    Research recommendation
    Published
    19 December 2018

  3. Transition between inpatient hospital settings and community or care home settings for adults with social care needs (NG27)

    This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.

    NICE guideline
    Published
    1 December 2015
    View recommendations

    Sections for NG27

  4. Discharging people from hospital

    conditions guideline People's experience in adult social care guideline Dementia guideline Care of dying adults guideline Home care...

  5. Improving wellbeing in care homes

    conditions guideline People's experience in adult social care guideline Dementia guideline Care of dying adults guideline Home care...

  6. Taking a person-centred approach to rehabilitation

    conditions guideline People's experience in adult social care guideline Dementia guideline Care of dying adults guideline Home care...

  7. Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with a cholinesterase inhibitor and memantine for people with Parkinson's disease dementia if treatment with a cholinesterase inhibitor alone is not effective or no longer effective?

    NG71/1 Question Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with a...

    Research recommendation
    Published
    15 October 2018

  8. How strong are the associations between hearing and visual loss, and sleep patterns and positive and negative health outcomes, in particular the development of dementia, disability and frailty? What are the most effective and cost-effective interventions to protect hearing and vision and improve sleep and what is their effect on the development of dementia, disability and frailty?

    positive and negative health outcomes, in particular the development of dementia, disability and frailty? What are the most effective...

    Research recommendation
    Published
    9 December 2015

  9. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  10. Anticholinergic burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual care?

    burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual...

    Research recommendation
    Published
    10 December 2018

  11. Technology appraisal and highly specialised technologies appeals

    Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.

  12. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Case management:- What is the effectiveness and cost effectiveness of high-intensity case management compared with usual care on quality of life (for the person living with dementia and for their carers) and the timing of entry to long-term care?

    compared with usual care on quality of life (for the person living with dementia and for their carers) and the timing of entry to...

    Research recommendation
    Published
    10 December 2018

  15. Falls (QS86)

    This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:

    Quality standard
    Last updated
    29 April 2025
    View quality statements

    Sections for QS86